Ibnsina Pharma
CASE:ISPH
£ 10,16
+ £0,46 (4,74%)
10,16 £
+£0,46 (4,74%)
End-of-day quote: 04/01/2026

Ibnsina Pharma Stock Value

The analyst rating for CASE:ISPH is currently Buy.
Buy
Buy

Ibnsina Pharma Company Info

EPS Growth 5Y
36,56%
Market Cap
£9,78 B
Long-Term Debt
£0,89 B
Quarterly earnings
05/20/2026
Dividend
£0,17
Dividend Yield
1,65%
Founded
2001
Industry
Country
Website
ISIN Number

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

£14,50
42.72%
42.72
Last Update: 04/01/2026
Analysts: 3

Highest Price Target £21,00

Average Price Target £14,50

Lowest Price Target £14,50

In the last five quarters, Ibnsina Pharma’s Price Target has risen from £1,89 to £6,34 - a 235,45% increase. Two analysts predict that Ibnsina Pharma’s share price will increase in the coming year, reaching £14,50. This would represent an increase of 42,72%.

Top growth stocks in the health care sector (5Y.)

×